STAT NewsOriginal article
STAT+: Pharmalittle: We’re reading about a Biogen Alzheimer’s drug, skyrocketing 340B drug sales, and more
Phase 2positivePositive
AI Analysis
Summary
Biogen's mid-stage Alzheimer's drug demonstrated positive results by slowing cognitive decline at rates comparable to approved medicines in a clinical trial.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
Slowed cognitive decline at roughly comparable rates as approved medicines
Importance:6/10
Sentiment:
0.65
Alzheimer'sclinical trialcognitive declinemid-stage
Related Companies
Read the original article
Published by STAT News on July 15, 2026 1:06 PM